Renin-Angiotensin banner
 lift button To visit another floor: Press the lift button, use the HTML version, or go to the reception
.
Select a room

search search

Advanced Search
Related resources
CV - Hypertension
CV - Post MI
Diabetes type 2
Heart failure
NPCi blog - cardiovascular
NPCi blog - diabetes

Links
NICE guidance on Hypertension - CG34
NICE guidance on Chronic Heart Failure - CG5
NICE guidance on Type 2 diabetes - CG87
NICE guidance on MI: secondary prevention - CG48
NICE guidance on Chronic Kidney Disease - CG73
SIGN guideline on Chronic Heart Failure - No. 95

Feedback
Please help us to improve this site by filling in our feedback form
National Support Materials

Renin-Angiotensin System Drugs - Workshop key icon Key Slides

 

Telmisartan▼ licence change
Since these NPCi materials were published, telmisartan▼ has been licensed for cardiovascular prevention (see Summary of Product Characteristics for details). To accompany this licence change, telmisartan▼ has become a black triangle drug intensively monitored by the MHRA and CHM. This licence extension does not change any of the messages in these materials.

View or download this PowerPoint presentation. You may find it useful in discussions about the choice of RAS drugs. Extensive notes for each slide are available in the word file.

PowerPoint Download a copy of the RAS drugs Key Slides
Flash Click here to view the RAS drugs Key Slides online
Word Download a copy of the RAS drugs Key Slides notes
   
 


 

A guide to the support materials for this topic is available in the library.

ACE-inhibitors and angiotensin-2 receptor antagonists (A2RA) drugs are used in a number of indications.  There are key slides relating to their use in some of these on other floors of NPCi.  Click on the links below to view them

They are also used in chronic kidney disease, for which there is NICE guidance (see especially section 1.8).

 

Date updated - February 2010

 

                                                 Terms & Conditions
 
npci npc home